Skip to main content Skip to main content
VitalDecades logo VitalDecades
Preventive care and screenings

Shield blood test for colon cancer: what it costs, when Medicare pays, and what it misses

Jennifer Walsh Preventive Health
11 min read

Who made it and how it was checked

By Jennifer Walsh, Preventive Health. Researched and drafted with AI assistance, then edited by the editor named here. Fact-checked by Sarah Whitcomb, Senior Health Editor, . Its sources are listed on this page. No licensed clinician has reviewed it. How we source.

Report an error on this page

Medicare Part B covers the Shield blood test every 3 years for people 45 to 85 at average risk with no symptoms, and you pay nothing if the provider accepts assignment; Medicare pays Guardant $1,495, the same as Guardant's listed cash price. A positive result needs a colonoscopy, which Medicare treats as part of the screening. In its trial Shield found 83% of cancers but 13% of advanced precancerous growths, and the American Cancer Society calls blood tests "not preferred."

If you have Original Medicare, are 45 to 85, have no symptoms and are at average risk, the Shield blood test for colorectal cancer costs you nothing once every 3 years when the provider accepts assignment. A colonoscopy after a positive result is covered as part of the same screening. Medicare pays Guardant Health $1,495 for each test, and Guardant's own site lists the same $1,495 as its cash price. What the price does not tell you: in the study that led to FDA approval, Shield detected 83% of colorectal cancers but only 13% of the advanced precancerous growths that a colonoscopy can remove, and the American Cancer Society, in guidance revised May 27, 2026, calls blood tests "not preferred."

On this page

What Shield costs you, by how you are covered

Read November 16, 2026, from Medicare.gov, CMS's coverage rule and fee schedule, and Guardant's coverage page.
Your coverageWhat you pay for ShieldWhat happens after a positive result
Original Medicare (Part B), 45 to 85, average risk, no symptoms$0 if the provider accepts assignment, once every 3 yearsFollow-up colonoscopy covered as a screening test: $0, unless a polyp is removed (then 15% coinsurance for the provider and, at a hospital outpatient department or surgery center, 15% to the facility; no deductible)
Medicare AdvantageFederal rules bar cost sharing for in-network Medicare-covered screening (42 CFR 422.100(k)); Guardant warns MA patients may still owe, so ask whether Guardant's lab is in your networkSame rule for the screening colonoscopy in network; ask the plan before testing
Private insuranceNot required at $0: the federal preventive rule follows the USPSTF, which does not include blood tests. Guardant names UnitedHealthcare as covering ShieldAsk the plan in writing whether the colonoscopy counts as screening
VA Community Care or TRICAREGuardant lists both as covering ShieldAsk the program
Paying cash$1,495, the rate Guardant lists "in the event the test is not fully covered by insurance"You pay for the colonoscopy separately

That last row is unusual. For routine lab tests, cash prices run well above Medicare's rate: in our lab price comparison, the cheapest cholesterol panel bought alone, fees included, costs 1.72 times what Medicare pays for the test and the blood draw. Shield's cash price and Medicare's payment are the same $1,495: CMS approved Shield as an advanced diagnostic laboratory test on March 10, 2025, and its list shows the $1,495 rate.

Who qualifies under Medicare's rule

Medicare's national coverage determination for colorectal screening (NCD 210.3) covers non-invasive biomarker tests like Shield "once every 3 years" for people 45 to 85 who have no signs or symptoms of colorectal disease and are at average risk, meaning no personal history of adenomatous polyps, colorectal cancer or inflammatory bowel disease, and no family history of colorectal cancer, adenomatous polyps or the inherited syndromes. The ordering clinician must give you "information about the test performance and the importance of a follow-on colonoscopy if the test returns a positive result."

The rule changed in 2026. The version effective June 8, 2026 (claims systems updated by January 4, 2027) renamed the category from blood-based to non-invasive biomarker tests and set two ways a test can qualify: at least 90% sensitivity with 87% specificity, or at least 79% sensitivity with 90% specificity, both from the FDA labeling, plus a requirement to meet the FDA's post-approval study to keep coverage. Medicare covers Shield under this rule. In the ECLIPSE study it had 83.1% sensitivity for cancer and 89.6% specificity for advanced neoplasia, which Guardant's materials round to 90%. Since January 1, 2025, a federal regulation (42 CFR 410.37(k)) has counted the colonoscopy after a positive blood or stool test as part of a complete screening, outside the usual frequency limits, which is why Medicare charges nothing for it unless a polyp is removed.

What Shield finds and what it misses

The FDA approved Shield on July 26, 2024 (PMA P230009) for colorectal cancer screening in adults 45 and older at average risk, with the instruction that "patients with a positive result should be followed by colonoscopy" and that it is "not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals." Approval rested on the ECLIPSE study, published in the New England Journal of Medicine in March 2024, which compared Shield with colonoscopy in 7,861 evaluable adults eligible for screening. In July 2026 the FDA approved a change to how Shield classifies results (supplement S010, a methylation-only model). We found no published performance figures for the changed test; the figures below are from the original ECLIPSE study, which Guardant still cites.

ECLIPSE results as reported in the study abstract (Chung et al., N Engl J Med 2024;390:973-983). The per-1,000 row is our arithmetic from the 10.4% positive rate.
MeasureResult
Colorectal cancers detected (sensitivity)83.1% (95% CI 72.2 to 90.3)
Stage I to III cancers detected87.5%
Advanced precancerous lesions detected13.2% (95% CI 11.3 to 15.3)
People without advanced neoplasia who tested negative (specificity)89.6%
Positive results per 1,000 people without advanced neoplasiaAbout 104

Two things follow. First, Shield is a cancer-finding test more than a prevention test. Colonoscopy, and to a lesser degree stool tests, can find precancerous growths so they are removed before they turn into cancer; Shield missed about 87 of every 100 such growths in the study, and Guardant's own materials say it has limited detection (55% to 65%) of stage I cancer. Second, roughly one in ten people without advanced growths gets a positive result and a colonoscopy that finds nothing serious. On Medicare that colonoscopy costs nothing unless a polyp is removed, but it is still a procedure, with bowel preparation, sedation and a small risk of complications.

What the guideline bodies say

The American Cancer Society's guideline page, last revised May 27, 2026, lists blood-based tests under "other test options": "Blood-based screening tests are not preferred screening options at this time," and "You should only use a blood-based test if you're not willing to get a stool-based test or visual exam." It gives no interval for them. The USPSTF's 2021 recommendation, the one federal coverage rules follow for private plans, "does not include serum tests, urine tests, or capsule endoscopy for colorectal cancer screening" because of limited evidence. Guardant says the NCCN guideline includes Shield; we could not read NCCN's text, which requires a login.

What three years of screening costs Medicare, by test

Medicare's 2026 national lab payment rates (CMS Clinical Laboratory Fee Schedule, October 2026 file), read November 16, 2026. Lab test only: no clinician visit, no colonoscopy. Totals are our arithmetic.
TestHow often (Medicare)Medicare pays the lab per testOver 3 years
Fecal immunochemical test (FIT)Every year$18.05 (code G0328)$54.15
Multi-target stool DNA, original CologuardEvery 3 years$508.87 (code 81528)$508.87
Multi-target stool DNA, next-generation markersEvery 3 years$591.92 (code 0464U)$591.92
Shield blood testEvery 3 years$1,495.00 (code 0537U)$1,495.00

On Original Medicare all four cost you nothing, so this table is about value, not your bill: the blood test costs the program about 28 times as much as three years of FIT, and the ACS lists FIT and the stool DNA test among its main options while calling the blood test not preferred. For a reader paying cash or facing a deductible, the gap is the reason to ask about a stool test first. Our guide to Cologuard versus colonoscopy compares those two in detail.

Who Shield is for, and who should skip it

A reasonable fit: someone at average risk who has put off screening because they will not do a colonoscopy or a stool test, and would do a blood draw. That is the group the ACS guideline names.

  • Not for you if you have symptoms such as blood in the stool, a change in bowel habits or unexplained weight loss. That calls for a diagnostic evaluation, usually a colonoscopy, not a screening test, and Medicare's rule excludes people with symptoms.
  • Not for higher-risk people: a personal history of colorectal cancer or adenomas, inflammatory bowel disease, or a family history of colorectal cancer or an inherited syndrome. Guardant's own limitations say the same.
  • Not within six months of a positive result on another colorectal screening test, per Guardant's limitations. A positive stool test needs a colonoscopy, not a second opinion from a blood test.
  • Over 85: Medicare's coverage ends at 85; our guide on when to stop colonoscopies covers the decision after 75.

Questions to ask before you order it

  • Would I do a stool test or a colonoscopy instead? If yes, those are the preferred options.
  • If the result is positive, where would I have the colonoscopy, and is it covered as screening on my plan?
  • On Medicare Advantage or private insurance: will you confirm in writing what I will owe for Shield and for a follow-up colonoscopy?
  • When would I repeat it? Medicare covers it every 3 years; results take about two weeks, per Guardant.

What we checked and what we did not

We read the FDA approval record, the ECLIPSE abstract on PubMed (title checked), Medicare's coverage determination NCD 210.3, 42 CFR 410.37, Medicare.gov's blood-based test and colonoscopy pages, CMS's 2026 fee schedule and its list of advanced diagnostic laboratory tests (which ties code 0537U to Shield at $1,495), Guardant's coverage and FAQ pages, the ACS guideline page and the USPSTF recommendation, all on November 16, 2026. We did not read NCCN's guideline, UnitedHealthcare's coverage policy, or the FDA's updated labeling.

Every figure, price and coverage rule on this page was checked against the pages listed under Sources on November 16, 2026. We did not take the test.

Frequently asked questions

How much does the Shield blood test cost?

On Original Medicare, $0 once every 3 years if you are 45 to 85, at average risk, without symptoms, and the provider accepts assignment. Without coverage, Guardant lists a cash price of $1,495, which is also what Medicare pays per test.

Does Medicare cover the Shield blood test?

Yes, under NCD 210.3, once every 3 years for people 45 to 85 at average risk with no symptoms. A colonoscopy after a positive result is covered as part of the screening.

Is Shield as good as a colonoscopy?

No. In its approval study it detected 83.1% of colorectal cancers and 13.2% of advanced precancerous lesions, while a colonoscopy can find and remove precancerous growths. The ACS calls blood tests not preferred and reserves them for people who will not do a stool test or a visual exam.

What happens if my Shield test is positive?

You need a colonoscopy. On Original Medicare it is covered as a screening test, so you pay nothing unless a polyp is removed, when 15% coinsurance applies. In the study, about 104 of every 1,000 people without advanced growths tested positive.

Does private insurance cover Shield?

It is not required to at no cost, because the USPSTF recommendation that private-plan preventive coverage follows does not include blood tests. Guardant says UnitedHealthcare covers it; ask your plan.

14 sources

These are the sources this guide cites, with each source's date where it publishes one. How we source.

Read next

Medicare annual wellness visit vs physical: what each one covers

Medicare's annual wellness visit is a prevention-planning conversation, not a physical exam, and Original Medicare does not cover a routine physical at all: CMS says patients pay 100% for one. The wellness visit and the one-time Welcome to Medicare visit cost $0 with assignment. Neither includes lab tests, which are billed on their own and are often free when covered. A bill usually comes from something else done at the same appointment, such as a problem treated there, charged as a separate visit with the $283 deductible and 20%. Read Nov 16, 2026.

Continue reading

Newsletter

One email a week: what changed, what it costs, what to do. Every item sourced and dated.

You're on the list. Look for your first issue next week.

No spam. Unsubscribe anytime.

Was this helpful?

Your feedback shapes what we cover next.

Thanks for letting us know.

If you found this useful, sign up for our newsletter to get more like this.

Thanks. What was missing?

Optional. We read every response.

Thanks.

We use this to prioritize the next round of edits.

Related Articles

More from Jennifer Walsh

More in Preventive care and screenings